Voting MachineWhile it is understandable that some frustration exists...many forget this is the same FDA who granted Orphan Status, Fast Track and Priority Review. Sounds like the problem is with Wuxu and it will eventually be addressed. Sure, time value of earnings and possibly a higher discount rate - but many smart people on this board thought we would be over $10 leading in to approval. Not saying I am not disappointed - but being Rational is more effective and today’s drop could be a great opportunity for a fund manager to take a position.